Twist Bioscience Reports Strong Q2 2026 Financial Results and Raises Guidance

Details

The company also raised its revenue guidance for the full fiscal year to a range of $442 million to $447 million, up from the previous guidance of $435 million to $440 million. Additionally, Twist Bioscience achieved a gross margin of 51.6% in Q2 2026, an improvement of approximately 2 margin points from the same period in 2025. The company expects to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026. Recent highlights include entering into a bispecific licensing agreement and launching new library preparation kits.

Items reported

About Twist Bioscience Corporation

Twist Bioscience Corporation is a pioneering biotechnology firm revolutionizing the field of synthetic DNA. The company's primary function is to produce synthetic DNA using a proprietary silicon-based manufacturing platform, enabling the creation of high-quality, accurate, and cost-effective DNA at scale. Twist Bioscience's innovations impact multiple sectors, including pharmaceuticals, industrial chemicals, agriculture, and data storage, offering transformative solutions in drug development, crop protection, and genomic research. By leveraging its proprietary DNA synthesis platform, Twist Bioscience plays a vital role in the broader biotechnology market, facilitating advancements that drive progress in personalized medicine and sustainable practices. With its cutting-edge technology, the company provides researchers and businesses with access to a wide array of DNA products and solutions essential for scientific discovery and technological innovation, underpinning its significance in the expanding biotech landscape.